Skip to main content
. Author manuscript; available in PMC: 2016 Feb 15.
Published in final edited form as: Bioorg Med Chem Lett. 2015 Jan 6;25(4):763–766. doi: 10.1016/j.bmcl.2014.12.094

Table 1.

Analytical and in vitro activity data for S-alkylated PR73 analogs.

Peptide Composition MW Calc/Found RT [min] EC50 [nM] TREX-hFpn-GFP cells
PR73 C86H133N21O15S 1733.19/1734.34 47.11 4.2±0.3
PR73SA C98H151N21O19S 1959.46/1959.80 52.47 6.3±1.2
PR73SB C94H143N21O19S 1903.35/1904.58 49.44 10.4±1.2
PR73SC C92H139N21O19S 1875.30/1876.60 48.32 12.6±1.8
PR73SD C89H135N21O17S 1803.24/1803.66 46.60 218.1±13.4
PR73SE C94H140N22O17S2 1914.40/1915.02 48.52 34.0±5.4
PR73SF C96H151N21O19S3 1999.56/1999.80 52.89* 10.0±3.4
PR73SG C90H137N23O17S 1845.28/1846.59 49.33* 8.4±2.5
PR73SH C96H153N21O21P2S 2031.40/2031.33 52.18* 1.1±0.1

Analytical RP-HPLC was performed using an analytical reversed-phase C4 XBridge™ BEH300 column, 4.6×150 mm, 3.5 μm (Waters, Milford, MA), or (*) an analytical reversed-phase C18 SymmetryShield™ column, 4.6×250 mm, 5 μm (Waters, Milford, MA).